AstraZeneca PLC (AZN) Stock Analysis
AstraZeneca PLC (AZN) is a multinational biopharmaceutical company headquartered in the UK, specializing in the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, respiratory, and immunology. Investors research AZN for its diversified drug portfolio, strong pipeline, and exposure to high-growth therapeutic areas, though the company faces typical pharma sector risks including patent expirations and regulatory uncertainty.
Get a full AI research report on AZN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AstraZeneca PLC do?
AstraZeneca generates revenue by discovering and developing prescription medicines, then manufacturing and commercializing them globally. The company operates across six main therapeutic areas: oncology (including Tagrisso, Lynparza, Enhertu), cardiovascular and renal metabolism (Brilinta, Farxiga), respiratory and immunology (Symbicort, Fasenra, Tezspire), vaccines and immune (Beyfortus, Evusheld), and specialty care products. Revenue is derived from direct sales to healthcare systems, hospitals, and pharmacies, with profitability dependent on patent protection, pricing power, and successful clinical development of pipeline candidates.
Bull case
- ✓Forward P/E of 14.03 suggests the stock trades at a discount to its trailing P/E of 23.98, potentially reflecting market expectations for future earnings growth from pipeline advancement.
- ✓Gross margin of 81.69% and operating margin of 23.46% demonstrate strong pricing power and operational efficiency typical of successful branded pharmaceutical companies.
- ✓Net margin of 17.02% and ROE of 21.97% indicate the company converts sales into profit effectively and generates solid returns on shareholder equity.
- ✓Diversified portfolio across oncology, respiratory, cardiovascular, and vaccines reduces dependence on any single therapeutic area or blockbuster drug.
Bear case
- ✗High debt-to-equity ratio of 64.23% indicates substantial leverage, which limits financial flexibility and increases refinancing risk in a rising interest rate environment.
- ✗Current ratio of 0.886 and quick ratio of 0.664 suggest potential near-term liquidity constraints, as current liabilities exceed current assets.
- ✗PEG ratio of 1.35 combined with forward P/E of 14.03 implies the market may be pricing in moderate growth expectations relative to earnings multiples in the sector.
- ✗Pharmaceutical industry faces ongoing patent cliff risks as blockbuster drugs lose exclusivity, requiring continuous pipeline success to maintain revenue growth.
- ✗Regulatory and clinical trial risks are inherent to drug development; pipeline candidates may fail to achieve efficacy or safety endpoints, impacting future revenue.
AZN valuation & financial health
AstraZeneca trades at a trailing P/E of 23.98 with a forward P/E of 14.03, suggesting the market anticipates earnings growth over the next 12 months. The company's gross margin of 81.69% reflects strong pricing on branded drugs, while an operating margin of 23.46% and net margin of 17.02% demonstrate operational leverage and profitability. However, the debt-to-equity ratio of 64.23% and current ratio of 0.886 raise questions about capital structure and short-term liquidity; the company carries meaningful debt relative to equity and has more liabilities due within 12 months than liquid assets. ROE of 21.97% and ROA of 8.02% show the company generates reasonable returns on capital despite the high leverage. A dividend yield of 2.07% with a payout ratio of 46.41% suggests management retains roughly half of earnings for reinvestment or debt service.
The bottom line
AstraZeneca presents a mixed financial profile typical of large-cap biopharmaceuticals: strong profitability margins and forward earnings expectations are offset by elevated leverage and tight near-term liquidity. Key factors to weigh include the company's ability to advance pipeline candidates to commercialization, manage patent expirations on mature products, and reduce debt levels over time. Investors should monitor quarterly pipeline updates, regulatory decisions on key candidates, and debt refinancing activity, as these will materially influence the risk-reward profile. The forward P/E discount to trailing multiples suggests the market has priced in some growth, but execution risk remains substantial.
Frequently asked questions
What does AstraZeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines globally. The company focuses on oncology, cardiovascular, respiratory, immunology, vaccines, and specialty care, with a portfolio of over 50 marketed drugs and a substantial pipeline of candidates in clinical development.
Is AZN a good stock to research?
AZN is a large-cap, established pharmaceutical company suitable for investors researching exposure to the healthcare sector and drug development. Whether it fits a specific investment strategy depends on individual risk tolerance, time horizon, and views on pharma sector dynamics; the company's strong margins and pipeline are offset by high leverage and patent cliff risks.
What is AstraZeneca's valuation?
AZN trades at a trailing P/E of 23.98 and forward P/E of 14.03, with a PEG ratio of 1.35. The forward P/E discount to trailing suggests the market expects earnings growth; whether this valuation is attractive depends on the probability and timing of pipeline success and the company's ability to manage debt.
Is AZN overvalued or undervalued?
Valuation is relative and subjective. The forward P/E of 14.03 is lower than the trailing P/E of 23.98, which could indicate either a discount if earnings are expected to grow, or a warning sign if growth is uncertain. Investors should compare AZN's multiples to pharma peers and assess pipeline risk to form their own view.
What are AstraZeneca's main risks?
Key risks include high debt-to-equity ratio (64.23%), tight liquidity (current ratio 0.886), patent expirations on mature drugs, clinical trial failures in the pipeline, and regulatory uncertainty. The company's ability to grow depends heavily on successful commercialization of new candidates and debt reduction.
Does AstraZeneca pay a dividend?
Yes, AstraZeneca pays a dividend with a yield of 2.07% and a payout ratio of 47.41%, meaning the company distributes roughly half of earnings to shareholders while retaining the remainder for reinvestment and debt service.
Research AZN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.